Your browser is no longer supported. Please, upgrade your browser.
Settings
RIGL Rigel Pharmaceuticals, Inc. daily Stock Chart
RIGL [NASD]
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own0.40% Shs Outstand118.91M Perf Week-0.84%
Market Cap279.44M Forward P/E- EPS next Y-0.66 Insider Trans-2.14% Shs Float118.77M Perf Month11.90%
Income-66.30M PEG- EPS next Q-0.16 Inst Own75.50% Short Float2.84% Perf Quarter-12.64%
Sales25.90M P/S10.79 EPS this Y43.90% Inst Trans1.60% Short Ratio4.43 Perf Half Y-16.37%
Book/sh0.69 P/B3.41 EPS next Y10.80% ROA-62.00% Target Price6.75 Perf Year1.29%
Cash/sh0.72 P/C3.28 EPS next 5Y60.00% ROE-86.50% 52W Range1.88 - 4.38 Perf YTD-1.26%
Dividend- P/FCF- EPS past 5Y-22.90% ROI- 52W High-46.35% Beta1.29
Dividend %- Quick Ratio4.20 Sales past 5Y-25.40% Gross Margin- 52W Low25.00% ATR0.12
Employees126 Current Ratio4.20 Sales Q/Q-70.80% Oper. Margin- RSI (14)50.54 Volatility4.79% 5.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-214.50% Profit Margin- Rel Volume0.81 Prev Close2.36
ShortableYes LT Debt/Eq0.00 EarningsMar 07 AMC Payout- Avg Volume762.75K Price2.35
Recom1.80 SMA203.55% SMA50-1.11% SMA200-12.42% Volume617,237 Change-0.42%
Aug-31-16Reiterated H.C. Wainwright Buy $6 → $7
Aug-30-16Reiterated Piper Jaffray Overweight $10 → $11
Jul-13-16Initiated H.C. Wainwright Buy $6
Jun-13-16Initiated Piper Jaffray Overweight
Apr-22-16Upgrade JP Morgan Neutral → Overweight
Apr-08-13Reiterated Stifel Buy $11 → $7
Nov-29-12Initiated UBS Neutral $9
Nov-06-12Reiterated Oppenheimer Outperform $12 → $15
Mar-26-12Initiated Canaccord Genuity Hold $8
Dec-10-10Downgrade MP Advisors Outperform → Market Perform
Mar-12-10Initiated Piper Jaffray Overweight
Nov-23-09Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-24-09Downgrade Citigroup Buy → Hold
Jul-10-09Upgrade Boenning & Scattergood Neutral → Outperform $20
Jul-09-09Reiterated RBC Capital Mkts Sector Perform $8 → $16
Jun-16-09Initiated Boenning & Scattergood Neutral
Jun-15-09Reiterated Jefferies & Co Buy $13 → $18
Jun-09-09Initiated Rodman & Renshaw Mkt Outperform $33
Mar-26-09Reiterated Jefferies & Co Buy $21 → $13
Feb-04-09Reiterated Stanford Research Buy $17 → $10
Feb-08-17 04:18PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Feb-03-17 04:01PM  Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares PR Newswire +9.91%
Jan-31-17 04:23PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Rigel Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jan-30-17 04:40PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial +5.05%
04:01PM  Rigel Announces Proposed Public Offering Of Common Stock PR Newswire
12:55PM  Why the Rigel Pharmaceuticals Update Could Signal Further Growth
07:30AM  Fostamatinib Study Results Continue to Trend Positive PR Newswire
Jan-16-17 07:30AM  Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Jan-05-17 07:30AM  Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy PR Newswire
Dec-14-16 04:02PM  Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio? at Insider Monkey
Nov-28-16 06:46PM  Hedge Funds Think The Skys The Limit For Horizon Global Corp (HZN) at Insider Monkey -5.26%
Nov-10-16 07:30AM  Rigel to Present at Jefferies 2016 London Healthcare Conference PR Newswire +6.97%
Nov-08-16 01:04PM  RIGEL PHARMACEUTICALS INC Financials
Nov-04-16 01:02PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : November 4, 2016 +5.60%
Nov-03-16 10:39AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
Nov-02-16 07:39PM  Edited Transcript of RIGL earnings conference call or presentation 1-Nov-16 9:00pm GMT
Nov-01-16 05:07PM  Rigel reports 3Q loss
05:00PM  Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:18PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update PR Newswire
07:07AM  Q3 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
Oct-28-16 07:30AM  Rigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results PR Newswire
Oct-25-16 10:52AM  Will Teladoc (TDOC) Show Any Improvement in Q3 Earnings?
Oct-23-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Oct-21-16 09:35AM  Rigel Tanks After Late-Stage Drug Failure (RIGL) at Investopedia -5.13%
Oct-20-16 02:24PM  Rigels stock rocked as all-in drug disappoints in late-stage trial at MarketWatch -15.22%
12:35PM  Why Rigel Pharma Is Falling at 24/7 Wall St.
11:48AM  Why Rigel Pharmaceuticals, Inc. Got Hammered Today at Motley Fool
11:45AM  Why Rigel Pharmaceuticals, American Airlines, Facebook, and More Are in the Spotlight at Insider Monkey
07:39AM  Rigel's bleeding disorder drug fails late-stage study
07:17AM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
07:00AM  Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP PR Newswire
Oct-19-16 08:41AM  Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : October 19, 2016
Oct-11-16 04:57PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh -5.04%
Oct-10-16 10:00PM  Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Oct-07-16 07:30AM  Rigel Expands Leadership Team in Research and Business Development PR Newswire
Oct-06-16 08:35AM  7 Key FDA Decisions and Clinical Trial Results Coming in Q4 at 24/7 Wall St.
Sep-16-16 12:55PM  Why this Peninsula biotech's layoffs aren't necessarily a bad thing (except for the 46 people losing their jobs) at bizjournals.com
Sep-15-16 10:57AM  Heres Why These Stocks Are Trending Today at Insider Monkey
08:02AM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
07:41AM  Rigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib at MarketWatch
07:30AM  Rigel Restructures to Focus on Fostamatinib Commercialization PR Newswire
Sep-14-16 09:28AM  Why Rigel Pharmaceuticals' Stock Soared in August at Motley Fool
Sep-01-16 08:37AM  BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated
Aug-31-16 11:46AM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : August 31, 2016 -14.25%
08:16AM  Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Aug-30-16 03:36PM  Rigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target +48.86%
03:25PM  What The Latest Data Means For Rigel Pharmaceuticals, Inc. (RIGL) at Insider Monkey
12:12PM  Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today at Motley Fool
10:05AM  Why Rigel Pharma Is Making a Run at 24/7 Wall St.
08:00AM  Rigel Pharmaceuticals Inc Conference Call to Discuss Its First of Two FIT Phase 3 Results of Fostamatinib scheduled for 8:00 am ET today
07:44AM  Rigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug
07:09AM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi
07:00AM  Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP PR Newswire
Aug-29-16 05:34PM  Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016 PR Newswire
Aug-23-16 11:36AM  What Were Looking For From The Upcoming Rigel Pharmaceuticals, Inc. (RIGL) Data at Insider Monkey
Aug-19-16 01:11PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : August 19, 2016
Aug-08-16 02:39PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : August 8, 2016
Aug-05-16 11:32AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 +5.48%
Aug-04-16 01:25PM  Edited Transcript of RIGL earnings conference call or presentation 2-Aug-16 9:00pm GMT
Aug-02-16 06:25PM  Rigel reports 2Q loss
04:18PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update PR Newswire
07:07AM  Q2 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
Jul-26-16 07:30AM  Rigel Announces Conference Call and Webcast to Report Second Quarter 2016 Financial Results PR Newswire
Jul-18-16 02:14PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : July 18, 2016
Jul-17-16 10:35AM  4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside at 24/7 Wall St.
Jul-13-16 07:15AM  Coverage initiated on Rigel Pharma by H.C. Wainwright
Jun-02-16 07:30AM  Rigel to Present at Jefferies 2016 Healthcare Conference PR Newswire
May-31-16 12:31PM  Most Popular Healthcare Stocks Under $5 at Insider Monkey
May-19-16 07:54PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : May 19, 2016
May-17-16 03:54PM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q1, 2016 By the Numbers
May-12-16 04:22PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-05-16 07:30AM  Rigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting PR Newswire
May-04-16 10:25AM  Edited Transcript of RIGL earnings conference call or presentation 3-May-16 9:00pm GMT -7.30%
May-03-16 05:32PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
05:00PM  Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today
04:28PM  RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
04:05PM  Rigel Announces First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close CCBN
Apr-26-16 07:30AM  Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results PR Newswire
Apr-12-16 07:30AM  Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference PR Newswire
Apr-01-16 07:30AM  Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP PR Newswire +6.73%
Mar-15-16 12:53PM  ETFs with exposure to Rigel Pharmaceuticals, Inc. : March 15, 2016
Mar-14-16 10:25AM  Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-09-16 04:58PM  Edited Transcript of RIGL earnings conference call or presentation 8-Mar-16 10:00pm GMT
Mar-08-16 05:00PM  Rigel Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today -9.92%
04:37PM  Rigel reports 4Q loss
04:22PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Rigel Announces Fourth Quarter and Year End 2015 Financial Results PR Newswire
04:03PM  Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer PR Newswire
07:07AM  Q4 2015 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
Mar-01-16 07:30AM  Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial Results PR Newswire
Feb-29-16 07:30AM  Rigel to Present at Cowen and Company 36th Annual Health Care Conference PR Newswire
Feb-25-16 07:30AM  Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia PR Newswire
Jan-29-16 05:04PM  RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh +6.59%
Jan-28-16 07:52AM  Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT) at noodls
07:30AM  Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT) PR Newswire
Jan-07-16 07:30AM  Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire -5.41%
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology. It is developing fostamatinib, an oral spleen tyrosine kinase inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and in Phase II clinical trials for autoimmune hemolytic anemia and IgA nephropathy; R348, an ophthalmic janus kinase/spleen tyrosine kinase inhibitor that is in Phase II clinical trials for the treatment of patients with ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of certain janus kinase inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled janus kinase inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and with Daiichi Sankyo to pursue research related to a specific target from a novel class of drug targets called ligases, as well as a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duliege Anne-MarieChief Medical OfficerJan 03Sale2.415,00012,0280Jan 13 06:02 PM
PAYAN DONALD GEVP, Pres. Discovery&ResearchAug 30Sale4.005,30321,21453,031Sep 01 06:18 PM